Lenalidomide (Len) is a crucial treatment for multiple myeloma (MM), improving progression-free survival (PFS), but it often causes a rash that leads to dose reductions or interruptions.

Read More> https://multiplemyeloma.pocn.com/treatment/dupilumab-effectively-manages-lenalidomide-induced-rash-in-patients-with-multiple-myeloma/